Drug Profile
Trebananib - Amgen
Alternative Names: 20060439; AMG-386Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Dana-Farber Cancer Institute; Gynecologic Oncology Group; Merck Sharp & Dohme; National Cancer Institute (USA); Quantum Leap Healthcare Collaborative; Roswell Park Cancer Institute; Takeda
- Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
Most Recent Events
- 07 Jul 2022 3683793=NCT01042379 trial removed from profile
- 28 Sep 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 09 Dec 2019 Amgen completes a phase II trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in the US, Canada, Australia, Belgium and India (NCT00479817)